DDInter698 DDInter53
Etidronic acid is a first generation bisphosphonate similar to [clodronic acid] and [tiludronic acid]. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]. Etidronic acid was granted FDA approval on 1 September 1977.
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Etidronic acid {u} (Compound) resembles {v} (Compound) Alendronic acid
Alendronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) resembles {v} (Compound) Alendronic acid
Alendronic acid {u} (Compound) resembles {v} (Compound) Ibandronate
Ibandronate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) resembles {v} (Compound) Ibandronate
Ibandronate {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) resembles {v} (Compound) Clodronate
Clodronate {u} (Compound) resembles {v} (Compound) Zoledronic acid
Zoledronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) resembles {v} (Compound) Risedronic acid
Risedronic acid {u} (Compound) resembles {v} (Compound) Alendronic acid
Alendronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) treats {v} (Disease) Paget's disease of bone
Paget's disease of bone {u} (Disease) is treated by {v} (Compound) Alendronic acid
Alendronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) resembles {v} (Compound) Ibandronate
Ibandronate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) binds {v} (Gene) PTPRS
PTPRS {u} (Gene) is bound by {v} (Compound) Alendronic acid
Alendronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) resembles {v} (Compound) Alendronic acid
Alendronic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid {u} (Compound) upregulates {v} (Gene) PLSCR1
PLSCR1 {u} (Gene) is upregulated by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Etidronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) resembles Clodronate (Compound) and Clodronate (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) resembles Risedronic acid (Compound) and Risedronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) treats Paget's disease of bone (Disease) and Paget's disease of bone (Disease) is treated by Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) binds PTPRS (Gene) and PTPRS (Gene) is bound by Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Etidronic acid (Compound) upregulates PLSCR1 (Gene) and PLSCR1 (Gene) is upregulated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib